SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis
Authors:
Open Access
- 21 December 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 85 (4) , 421-430
Abstract
Background: In the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination has been effective in preventing COVID-19 infections and related mortality. The SARS-CoV-2 vaccination was also recommended by the international society for patients with inflammatory bowel disease (IBD). However, IBD patients were not recruited in prospective randomized clinical vaccine studies. To evaluate the efficacy and safety of SARS-CoV-2 vaccination in IBD patients, we conducted this systemic review and meta-analysis. Methods: We systematically searched PubMed, Medline, and the Cochrane Library for studies published between January 1, 2019, and September 9, 2021. Studies written in English reported the efficacy, seroconversion (anti–SARS-CoV-2 anti-spike (S) antibody titer beyond the threshold) rate, and adverse events after the SARS-CoV-2 vaccination in IBD patients. We extracted the author, date, study design, country, types of SARS-CoV-2 vaccination, number of IBD patients receiving SARS-CoV-2 vaccinations, and study outcomes. Published data from the enrolled studies were pooled to determine effect estimates. The study protocol was registered in PROSPERO (CRD42021264993). Results: We analyzed findings from 27 454 IBD patients who received SARS-CoV-2 vaccinations in 11 studies that met the inclusion criteria. The post–SARS-CoV-2 vaccination COVID-19 infection rate was comparable between the IBD patients and non-IBD patients (odds ratio [OR], 1.28 [95% CI, 0.96–1.71]) and higher in nonvaccinated IBD patients compared with vaccinated IBD patients (OR, 8.63 [95% CI, 5.44–13.37]). The adverse event rate, severe adverse events, and mortality after the SARS-CoV-2 vaccination were 69%, 3%, and 0%, respectively. Conclusion: The SARS-CoV-2 vaccine is effective and tolerated in preventing COVID-19 infections in IBD patients. Over 98% of patients had seroconversion after receiving all doses of the SARS-CoV-2 vaccination, and the influence of biologics on vaccination was limited. The SARS-CoV-2 vaccination is recommended for IBD patients.Keywords
This publication has 49 references indexed in Scilit:
- Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysisGastroenterology, 2020
- Gastrointestinal and liver manifestations in patients with COVID-19Journal of the Chinese Medical Association, 2020
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected PneumoniaNew England Journal of Medicine, 2020
- The outbreak of COVID-19: An overviewJournal of the Chinese Medical Association, 2020
- ACG Clinical Guideline: Preventive Care in Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2017
- 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised HostClinical Infectious Diseases, 2013
- Safety and Utilization of Influenza Immunization in Children With Inflammatory Bowel DiseasePediatrics, 2013
- Long term safety and efficacy of H1N1 vaccine in a single-center cohort of IBD patients treated with immunomodulators and/or anti-TNFα biologicsJournal of Crohn's and Colitis, 2012
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Conducting Meta-Analyses inRwith themetaforPackageJournal of Statistical Software, 2010